HON vs PFE: Which Is the Better Buy?
Side-by-side comparison of Honeywell International Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Honeywell International Inc. · Industrials
$212.55
-8.5% upside to fair value
Med Conviction
Grade C
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+12.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
HON |
PFE |
| Current Price |
$212.55 |
$27.64 |
| Fair Value Estimate |
$194.50 |
$30.94 |
| Upside to Fair Value |
-8.5%
|
+12.0%
|
| Market Cap |
$67.4B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
7.4x
|
17.4x
|
| Price / Sales |
1.9x
|
2.5x
|
| Price / FCF |
16.4x
|
14.3x
|
| Revenue Growth YoY |
-6.1%
|
+2.6%
|
| Gross Margin |
36.6%
|
71.3%
|
| Operating Margin |
14.1%
|
25.1%
|
| Return on Equity |
41.7%
|
4.9%
|
| Dividend Yield |
2.09% |
6.22% |
| FCF Yield |
6.11%
|
6.97%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Honeywell International Inc. is a 101,000-employee diversified industrial technology and manufacturing conglomerate, led by CEO Vimal Kapur, spanning Aerospace, Building Technologies, Performance Materials and Technologies, and Safety and Productivity Solutions. Business quality is solid but not exceptional: the company carries a durable intangible-asset and switching-cost moat in aerospace avion…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
HON |
PFE |
| Zone Low |
$145.88 |
$23.21 |
| Zone High |
$165.32 |
$26.30 |
| In Buy Zone? |
No
|
No
|